Ann: Kazia releases final data from P2 paxalisib trial, page-9

So let's see, Pax works better in the 2/3 of patients which the standard of care does not work at all in than the SOC works in the 1/3 of the patients where it (SOC) does work.
I'm guessing the market for Pax is twice that of the market for Temozolomide.

With supporting analyses, which Kazia has been doing, FDA could consider an approval, at least on a provisional basis. Depends on whether the company wants to ask for one.